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Abstract 
 
Our goal is to make a positive impact in the cervical cancer diagnostic space through the 
development of an accurate, cost effective solution that enables women in low resource settings to 
test for cervical cancer on a frugal and effective platform. In developed countries, we rely on 
regular preventive care, such as pap smears, to identify any cellular abnormalities that may indicate 
the disease state. However, due to the high cost and laboratory requirements of this procedure, 
women in low resource settings typically do not have access to this procedure. Since they are not 
regularly screened and often have little knowledge of cervical cancer, they are 
unaware of symptoms and physiological changes that mark the progression from human 
papillomavirus (HPV) infection to cervical cancer. Because of the seemingly benign symptoms of 
the disease, cervical cancer is the third most common form of cancer in women and the second 
leading cause of cancer related death in women worldwide. There are alternative methods available 
to detect the presence of high grade lesions in the cervix, but these methods are invasive and 
difficult to accurately interpret without the presence of a medical professional. Therefore, we are 
attempting to create a low cost, non-invasive, cancer-specific detection system based on urinalysis 
biomarker assays. We hope to launch our device in conjunction with an educational program that 
focuses on women’s health, HPV, cervical cancer, and basic instructions for usage and 
interpretation of our product.  
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CHAPTER 1: Introduction 
 
1.1 Cervical Cancer in Developing Countries 
Cervical cancer is the third most common form of cancer in women around the world, of which 
about 80% of cases occur in lower income countries. The areas primarily affected by the disease 
include sub-Saharan Africa, Central America, and Melanesia.[1] This imbalance is primarily due 
to the lack of regular preventive care or screening of precancerous lesions, an intervention that has 
long since been in place in the United States. Studies estimate that while cervical screening rates 
in developed countries meet or exceed the 50% mark for the past 5 years, only 5% of women who 
reside in developing countries have had access to screening for cervical dysplasia.[1] The disparity 
in cervical cancer rates between developed and developing countries is also due to the high cost of 
the newly developed vaccinations that have been deployed and established as routine care in most 
of the developed world. Due to the long development period of cervical cancer, which can take as 
long as 20 years to progress from a mere HPV infection to an invasive carcinoma, there are many 
opportunities to detect and treat the disease in its earliest stages. 
 
1.2 Human Papillomavirus to Cervical Cancer 
Human Papillomavirus (HPV) is one of the most common sexually transmitted infections, such 
that almost every sexually active individual will be infected at some point in their lives.[2] There 
are over 40 types of HPV that can be spread through direct sexual contact, which fall into two 
categories: low-risk and high-risk HPV.[3] Low-risk HPV can cause genital warts, while high-risk 
HPV may cause cervical cancer in rare cases. Of all the high-risk strains, HPV 16 and 18 are 
responsible for approximately 70% of all cervical cancer cases. These strains infect epithelial cells 
and can lead to cervical intraepithelial neoplasia, of which the most severe cases may progress into 
cervical cancer (CC).[3] CC occurs when the cells lining the cervix, the lower part of the uterus, 
begin to grow out of control. Most cases begin in the transformation zone, an area where the two 
different parts of the cervix, covered by two different types of cells, converge. When abnormalities 
arise from this cellular conversion, they are referred to as cervical intraepithelial neoplasias (CIN). 
There are three disease states associated with CIN, separated into stage 1, 2 and 3. These states 
describe the extent the abnormal cells have expanded through the surface layer of the cervix, as 
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well as treatments needed to remove the cells. CIN1 affects one-third of the thickness of the surface 
layer of the cervix, indicating mild changes that often do not lead to cancer. The treatment methods 
for CIN1 is often a medical recommendation for continued monitoring. CIN2 affects two-thirds of 
the surface layer, indicating moderate changes. At this stage, there is a possibility that cancer is 
involved. CIN3 (also known as carcinoma-in-situ) indicates more severe changes. Although it still 
may not specify cancer, it needs to be treated as soon as possible.[4] None of the disease states 
cause symptoms, which is why cervical screening is imperative. There are three main types of 
cervical cancers: squamous cell carcinomas, adenocarcinomas, and mixed carcinomas. These 
cancers often occur in women aged 20-50. The normal cells of the cervix gradually develop 
through stages of “pre-cancer.” Although only some of the women in the pre-cancer stage will 
develop cervical cancer, treating all cervical pre-cancers is the safest way to ensure a lower 
prevalence rate.[5] 
 
There are several measures that can be taken to prevent HPV and CC. One of these measures is 
practicing safe sex, particularly through the use of condoms or safety informed sexual practices. 
Other ways to reduce the risk are to avoid smoking and to be vaccinated. The vaccine works to 
prevent HPV infection, but cannot treat an already existing infection.[5] Prior vaccines have only 
protected against strains 16 and 18, the high-risk strains of HPV, but the newer vaccine protects 
against those and also two other strains that often lead to genital, anal, or oral warts.[6] 
Additionally, having many children or a weakened immune system, such as those with HIV/AIDS, 
can also increase the risk of infection with high-risk HPV.[7] Currently, there are no treatments 
for HPV infections; however, symptoms like genital warts, benign tumors, and cancerous changes 
in the cervix resulting from HPV can be treated.[3] There are several methods of treatment for the 
common types of CC including surgery, radiation therapy, chemotherapy, and targeted therapy. 
The most commonly used screening method in developed countries is the Papanicolaou (Pap) test, 
a procedure that collects cells from the cervix and analyzes them under a microscope to find cancer 
and pre-cancers.[5] 
 
1.3 Case Study: Tanzania 
Tanzania is a country of just under 54 million people, with a median age of only 17.7 years. This 
is the largest population of East African countries, but it also has the lowest population density, 
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meaning that about a third of the population lives in rural conditions. There is a significantly high 
fertility rate, such that each woman will typically bear between 4 and 5 children in their lifetime, 
with the median age of the first birth occurring at around 19.8 years. The average school life 
expectancy is only 8 years for both men and women, and the contraceptive prevalence rate is 
38.4%.[8] With such a significant portion of the population being so young and sexually active, 
and the lack of education or usage of physical contraception, there comes great risk for serious 
sexually transmitted diseases, such as HIV and HPV.  Tanzania has the 6th highest rate of 
incidence of cervical cancer in the world, with 54 cases per 100,000 people.[9] About 3.3% of 
women have HPV 16 or 18, which will likely develop into cervical cancer.[10] In addition to 
having such high rates of incidence, Tanzania is one of a few countries in Africa that is prioritizing 
improving screening methods for this disease. However, only 12 of the 21 regions in Tanzania 
have screening clinics and only 1 in 20 women in Tanzania are screened for cervical cancer.[11]  
 
1.4 Review of Existing Screening Methods 
1.4.1 Current and Novel Approaches 
The current medical standards for screening and prevention of HPV and cervical cancer are the 
Pap test and the HPV vaccine. The HPV vaccine is suggested for children to prevent against new 
HPV infections, however, it cannot cure any existing infections. [5]  Because of this, women are 
suggested to receive routine screening of the cervix with a Pap test.  Pap smears are highly 
invasive, as it requires a sample to be directly taken from the cervix and must be done by a trained 
clinician.[5] The microscopic analysis of this sample in a lab can cost hundreds of dollars per 
person, which is not a viable option in countries where many people do not consistently receive 
basic welfare check ups.  
 
A more specific alternative to the pap test is Roche’s CINtec histology. Roche’s CINtec histology 
test for HPV is more specific than a pap test because it uses two biomarkers: p16 and Ki-67. The 
test requires a biopsy of the patient to be taken and used to quantify the amount of p16 and, Ki-67 
present, as well as 12 pooled hrHPB markers for HPV16 and HPV18. The test confirms the 
presence of high-grade cervical tissue and can confirm precancerous cervical lesions that are 
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generally missed by the staining that is used for pap tests. The test was recently FDA approved as 
a result of the Cervical Tissue Adjunctive Analysis Study.[12]  
 
1.4.2 Current Low Cost Methods of Screening 
A commonly used diagnostic method in lower-income countries is visual inspection by acetic acid 
(VIA). This method is a best applied in low-resource setting due to the low cost of implementation. 
The screening itself consists of application of acetic acid (ordinary table vinegar) to precursor 
lesions in the cervix that can be caused by HPV. A positive VIA test will turn these lesions white 
a few minutes after application. This test works quickly and provides patients with immediate 
results that can be coupled with treatment in the same visit. However, invasiveness, specificity, 
and sensitivity, are concerns that are not addressed by this screening method. A systematic review 
of studies about VIA indicated that specificity and sensitivity both had a large range from 65%-
95%. This results in many false positives.[13] Additionally, this method is not effective for women 
ages 50 or older because the testing area with lesions begins to recede into the endocervical 
canal.[14]  
 
Another diagnostic that is being used to limit the cost of cervical cancer screening is a modified 
colposcope. Scientists at Duke University have created a low cost, easily portable colposcope that 
can be attached to common devices like a smartphone and used by healthcare professionals. This 
device will impact follow up screening for those who have been diagnosed with high risk HPV or 
cervical cancer. However, a colposcopy is generally not the first indicator for cervical cancer nor 
does it address the issue of invasiveness or the need for medical professionals to analyze the images 
taken.[15]  
 
1.4.3 Critiques and Drawbacks of Current Methods 
From a public health perspective, the most notable drawbacks of current screening techniques and 
low-cost screening techniques is the invasiveness. The table in Appendix E outlines current 
diagnostics options for cervical cancer. The current diagnostic options assess are visual inspection 
by acetic acid, the pap test, a colposcopy, as well as Roche’s CINtec Histoloy Test.    
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1.5 Significance of Project 
As previously stated, more than 84% of cervical cancer cases occur in low resource settings, 
notably countries in Africa, Latin America, and the Caribbean. With Tanzania having the 6th 
highest rate of incidence in the world, at 54 cases per 100,000 people, [9] there is great need for a 
cervical cancer diagnostic compatible with the countries’ cultural norms, geographic vastness, and 
lack of medical development. However, Tanzania is one of a few countries in Africa that is 
prioritizing improving screening methods for this disease, meaning that they are likely to invest in 
programs that would fund ventures to decrease female mortality due to cervical cancer. Currently, 
only 12 of the 21 regions in Tanzania have screening clinics and only 1 in 20 women in Tanzania 
are screened for cervical cancer.[11] There is some work being done by local agencies to increase 
awareness of HPV and to pilot the HPV vaccine, [16] but there is great room for improvement. 
 
These factors represent a pathway for growth that can be achieved through the creation of this 
device. Our frugal detection device has the capacity to make a large impact by screening more 
women and launching an educational program, in conjunction, that can be deployed in all regions 
of Tanzania and other parts of the word. It will be non-invasive, accurate, and can be used without 
the need of a medical professional. Being that the progression of this cancer is highly preventable 
with intervention, increased rates of early detection can greatly lower the mortality of cervical 
cancer in countries like Tanzania.  
 
1.6 Project Goals, Objectives, and Expected Results 
1.6.1 Project Goal 
Our goal is to design a cost-effective solution that enables women in developing countries to test 
for cervical cancer in a low cost and effective platform. By the end of the academic year, we hope 
to validate our assays and design an immunochromatographic lateral flow assay that will detect 
stage 0 and stage 1 cervical cancer biomarkers in mock urine. Currently, we would like to test for 
two biomarkers: the polyamine spermine, which has been shown to be significantly upregulated 
during cervical cancer, and the p16 protein, which is strongly expressed in high grade lesions and 
invasive cervical cancer.  
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We chose our biomarkers purposefully to specifically test for cervical cancer as opposed to just 
HPV infection, because of the natural self-clearing properties of most infections. The two markers 
together will theoretically identify the presence of cervical cancer, although there is the possibility 
of detecting unspecified cancer or an HPV infection without the presence of cancer; both of which 
would be helpful results. A positive cervical cancer test result will display: Spermine (+) and p16 
(+). The first biomarker, a polyamine, has been associated in the development of cervical cancer, 
with a substantial increase in concentration in the serum, plasma, and urine of subjects with cancer. 
Physiologically, polyamines have been seen to mediate immunosuppressive effects in vitro due to 
their oxidation products; it is theorized that this effect explains their presence during cervical 
cancer.[17] The second biomarker, which is the protein product of the p16 gene, is strongly 
expressed during high grade lesions and invasive cervical cancer.[18] The protein concentration 
of p16 in urine is still undetermined due to lack of literature on the subject, but our device will act 
as a proof of concept onto which more research can later be done. Initially, we hoped to also test 
for the HPV L1 protein capsid to help distinguish an HPV infection from cervical cancer; however, 
the biomarker was left out of our final design as the concentration of the L1 protein is not yet 
known in urine. 
 
1.6.2 Objectives 
Our objectives are to make our diagnostic easily accessible because many our customers live in 
remote areas. We want to have high true positives and low false negatives, as other diagnostic 
methods typically have a low true positive rate. Often this requires the women to undergo more 
invasive measures to confirm the presence of the disease. We desire our solution to be non-
invasive, since invasive treatments can be a deterrent both culturally and physically. We aim for 
our device to be easy for patient to administer, so they do not have to go to a health clinic that is 
potentially far from their house to get tested. We would like our product to be manufactured at a 
low cost in the country of implementation, to prevent customers and clinics from run out of 
supplies and having to wait for them to be imported. We hope to implement an educational 
program with our solution so that women can learn the signs and symptoms and get tested before 
the cancer metastases. We presented these objectives to scientists who worked with Ghanaian 
people to train them in detecting cervical cancer by visual acetic acid. They approved of our 
objectives and provided feedback. 
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To determine whether our objectives are met, we expect our product to consistently test 
specifically and sensitively for p16 and spermine. After validating the Enzyme Linked 
Immunosorbent (ELISA) assays for each of these biomarkers, we expect to be able to incorporate 
these assays on to a lateral flow assay (LFA), which provides the optimum form of diagnostic 
device for the population we are targeting due to the low-cost and easily storable properties of the 
assay.  
 
1.6.3 Expected Results 
We outline the results one would expect to see if they used our microfluidic urinalysis diagnostic 
depending on their respective health status (Table 2). If the individual is infected with HPV, then 
there is a small possibility that they may receive a positive diagnosis from the p16 LFA, if the 
infection is accompanied by high risk lesions. If the diagnostic expresses a positive marker for 
spermine, then one can infer that it is indicative of the presence of cancer somewhere in the body. 
If this diagnosis is obtained it is important for the patient to seek medical attention regardless of 
the HPV diagnosis. Finally, if there is a positive marker on both the HPV assay and the spermine 
assay, the we can assume that the patient is very likely has cervical cancer.  
 
 
 
Table 2: Expected Results from Frugal Diagnostic 
Potential 
Health 
Status 
No Disease Low Risk 
HPV 
Infection  
High Risk 
HPV 
Infection  
General 
Cancer 
Invasive 
Cervical 
Cancer 
Spermine - - - + + 
p16 - - -/+ - + 
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1.6.4 Alternative Plan 
If we are unable to validate assays for both biomarkers, then we hope to focus on validating an 
LFA assay for one biomarker. This biomarker will most likely be spermine, as the concentrations 
of spermine in an individual who is healthy and in an individual who has cervical cancer is 
published. After we validate the ELISA assay, we plan on optimizing it to fit a lateral flow assay, 
which is the optimum diagnostic for our target population.  
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CHAPTER 2: Systems Level 
2.1 Customer Needs 
Prior to the creation of our diagnostic, we felt that reaching out to the customer was essential in 
order to develop a device that was relevant to their needs and compatible with the area. We began 
by attempting to make contact with the women and healthcare providers of Tanzania on our own; 
however, we quickly realized that it is easier to make contacts in our target population through our 
partner, the Frugal Innovation Hub. Through them, we reached out to healthcare providers, 
researchers, and organizations that have worked in conjunction with the women of Tanzania, or 
with cases of cervical cancer in comparable locations. Through this network, we were able to 
understand the outcomes that were most important to the target population, and tailor our device 
to best meet those needs.  
 
2.1.1 Customer Interviews and Literature Search 
According to IMA World Health, an organization that is working in Tanzania on the cervical 
cancer crisis, the barriers to cervical cancer treatment include the following: lack of supplies, 
lack of follow up, and lack of education. If health care workers run out of supplies, they are no 
longer able to test for the disease. Unfortunately, due to the lack of funding and the expansive 
geography of Tanzania, running out of supplies is often the case with most outreach teams. 
Similarly, women are unlikely to follow up and get secondary pap smears if hospitals are located 
far from their homes. Due to the majority rural demographics of Tanzania, trips to the nearest 
established medical centers are often 50-100 km away from the remote villages in which these 
women live. Therefore, a trip can cost a woman a full day of work, and a significant portion of 
their wages in order to have access to a motor vehicle; both of which are significant impairments 
to their motivation for access. Finally, within Tanzania there is a lack of general education about 
women's health that is potentially due to cultural barriers, which leads to much confusion on the 
nature and symptoms of female specific diseases, particularly those that are spread via sexual 
infection.[19]  
 
We also reached out to Julia Kramer, a graduate student at UC Berkeley who is currently 
involved with research on cervical cancer in Ghana. She created a training simulator model to 
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assist in training midwives to detect cervical using visual inspection by acetic acid (VIA). 
Kramer suggested that one of the most significant issues was the lack of medical attention that 
the women typically receive. They often do not visit a hospital in their entire lifetime, aside from 
instances of severe illness or childbirth. Additionally, there is the significant issue of the 
promiscuity stigma that prevents conversations around sex and safe sexual practices. Therefore, 
she stated that the bigger challenge was in getting the women through the door, not in getting 
them to take the test. Finally, in response to our device Kramer stated that we may struggle with 
implementing the preventive testing at home due to the lack of precedent and the stigma of 
sexually transmitted infections; however, she suggested that the diagnostic could be deployed in 
village community centers where the residents receive basic health aid.  
 
2.2 Desired Outcomes  
From these resources and additional literature searches, we were able to come up with a set of 
outcomes and rank them on importance for the customer. The product must be/have: 
1. Easily accessible due to the challenges a woman may experience in reaching a hospital if 
she lives in a rural, like most women do.  
2. High true positives and low false negatives, as other diagnostic methods typically have a 
low true positive rate, often requiring the women to undergo more invasive measures to 
confirm the presence of the disease.  
3. Non-invasive, as invasive treatments can be a deterrent due to both cultural stigma, 
religious perspective, or fear of physical harm. 
4. Easy for patient to administer so they do not have to go to a health clinic that is 
potentially far from their house to get tested. 
5. Low cost manufacturing in the country of implementation so they don’t run out of 
supplies and there is no issue with deployment. 
6. Educational programs that accompanies the diagnostic so that the women can learn the 
signs and symptoms of HPV and cervical cancer, along with the ways in which is 
transmitted and potential safe practices. 
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2.3 Outcomes In Innovation 
Our outcomes led us to develop an assay that is more specific for stage 0 or stage 1 cervical 
cancer in urine compared to HPV or invasive cervical cancer. We hope to integrate the assay into 
a urine test that can be self-administered at home or in a village clinic, and be easy to read in a 
concrete and simple manner. The product will be manufactured in the country of implementation 
and include an educational program within the packaging. 
 
2.4 Project Components 
2.4.1 Biomarker Selection 
Before the creation of our cervical cancer diagnostic, it was necessary to select specific and 
scientifically backed biomarkers that would provide a strong foundation for the device. We spent 
a significant portion of our research on this section, as we deemed that it would reduce the 
credibility of our project if the biomarker were to be non-specific or non-functional. Therefore, we 
came up with five steps that were necessary to accomplish before any marker could be added to 
our device. 
 
The first step in this process was to confirm that the biomarker was upregulated during instances 
of cervical cancer. We did this by searching for panels of proteins, hormones, and antibodies that 
had been linked to CC in previous research. Once we found compounds that seemed to have a 
reliable relationship with CC, the second step consisted of looking into the urine panels of patients 
to confirm that this compound could be detected in urine. This was an essential step because a core 
outcome of our diagnostic consisted in it being noninvasive, a quality that would be negated by 
many other bodily fluids. If the biomarker had history of occurring in urine, then we would proceed 
to the third step, which was finding the concentration of the biomarker in the urine of a healthy 
individual versus that of a diseased individual. This step was essential to the process, and also the 
most difficult to surpass. Due to the fact that there is no urinary cervical cancer screening 
precedent, there was not a lot of literature measuring the concentrations of protein in the urine of 
cervical cancer patients. However, we managed to locate quite a few biomarkers that were 
measured in urine, and in which the difference in healthy and diseased concentrations was 
significant. For the fourth step, we simply looked up what the conventional testing methods were 
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for the biomarker, which led us to the fifth step of identifying a detection method that was 
compatible with the target population. This meant that the detection method had to be frugal, 
effective, and require minimal external aid.  
 
2.4.2 Device Format 
We chose to deploy our diagnostic on a lateral flow assay (LFA) due to the significant 
advantages that this method has over other assay formats, particularly in the context of 
deployment in Tanzania, where there is no guarantee for electricity, clean water, sterile 
conditions, or an experienced technician. LFA’s are a low-cost diagnostic test that operates on 
the use of antibodies, colored particles, and several physical pad components, to give a definitive 
confirmation regarding the presence or absence of analyte. These tests typically have long shelf 
lives, and do not require refrigeration or special care, like many other diagnostic tests. Another 
benefit of an LFA is that it requires minimal training and no additional processing after use, 
which makes it well suited to act as a field based diagnostic necessary for our target population, 
Tanzania. Because these tests are powered only by capillary action, they do not require an energy 
source and provide a reading within 20 minutes of testing. Similarly, they only require a small 
amount of liquid sample in order to produce a result. In terms of sensitivity, LFA’s have better 
sensitivity and specificity than other well established methods under optimal conditions; 
however, depending on the analyte and antibody used there may be cases of low biomolecule 
affinity.[20] 
 
Although LFA’s have significant advantages, there are a few drawbacks that demand the assay 
be designed with careful consideration of the analyte. To begin with, these tests are at most semi-
quantitative, and typically only qualitative. This is due to the nature of the results, which is one 
line for a negative reading, and two or more lines for a positive reading. However, we consider to 
be beneficial to our aims as it reduces the complexity in reading the device output. Depending on 
who is making the LFA batch, reproducibility of the test can vary significantly because of the 
manual fixation of antibodies and colored particles. Depending on the specific experiment, the 
sample may have to be pretreated, or the nitrocellulose blocked, for optimal testing. Finally, 
because capillary action is the only energy involved in this assay, once the sample is applied it 
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can neither be sped up or slowed, and the properties of the sample may affect the speed of the 
reaction.  
 
2.4.3 Educational Component 
In addition to the creation of our device, we hope to launch an educational component. This could 
be in the form of a pamphlet that serves to educate women on sexually transmitted diseases, the 
progression of HPV into cervical cancer, and women’s health in general. Ideally, this will increase 
the impact of our project by providing women with information that can be taught to others in their 
communities. Thereby, educating the population as a whole and eventually leading to decreased 
rates of incidence and mortality due to cervical cancer. 
 
2.4.4 Project Pipeline 
In order to outline the various components of our project and their relationship to each other, we 
developed a pipeline (Figure 1). The first component is public outreach. This will involve creating 
an infrastructure and distribution system for basic information regarding sexually transmitted 
disease, HPV, cervical cancer, and the benefits of routine screening. The educational component 
would ideally include the creation of pamphlets outlining the disease stages and treatment options.  
Additionally, it would involve creating partnerships with community health workers that could 
provide valuable information on HPV and cervical cancer. 
 
Within this pipeline, we hope to be able to route the users of our device to the help that they need.  
This would entail providing proper support and guidance for those who obtain routine screening 
with CERVIS depending on their result. Whether the community members test positive for HPV, 
cervical cancer, or test negative for both outcomes, we hope to have a clear network established 
that can ensure the user is able to get the support they need.  
 
We want to emphasize the importance of follow up and continued screening for the detection and 
prevention of disease progression. Each screening will include a test with our CERVIS device as 
well as explanation of results and direction of the next steps. A negative result would result with 
no indication of HPV or cervical cancer and would require no additional action, aside from routine 
screening. If the user tested positive for HPV, more frequent routine screening would be suggested. 
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A positive result for CC or general cancer would result in the patient being advised to seek further 
medical attention to confirm the diagnosis and get treatment. We hope to connect our users to 
healthcare professionals in their respective countries, so that there is a clear treatment method 
following the diagnosis of cervical cancer.  
 
Figure 1: Project Pipeline 
 
2.5 Team and Project Management 
2.5.1 Team Management 
Our team is composed of two SCU faculty members, three bioengineering students, three public 
health students from the Engineering World Health partnership, and two independent researchers. 
Our faculty members are Dr. Prashanth Asuri, who acts as our bioengineering advisor, and Dr. 
Michele Parker, our Engineering World Health (EWH) advisor. The public health students 
partnered with us through EWH are Christina Kraus, Lea Daran, and Alyssa Miawotoe. Our project 
originally stemmed from the work of Dr. Hernandez, a researcher at the University of Hawaii, who 
has since provided us with further information regarding HPV biomarkers and potential diagnostic 
tools. Finally, we are also in contact with Julia Kramer, a UC Berkeley Graduate student who 
created a training simulator model to help midwives detect cervical using acetic acid. Her 
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contribution to our project has been mainly in informing us of the target population and shaping 
our customer outcomes. Within our primary bioengineering group, Eva Bouzos acts as the primary 
liaison for Dr. Asuri, Ivy Fernandes interfaces with Dr. Hernandez, and Marina Predovic 
communicates with the public health students.  
 
2.5.2 Budget 
We requested that the Santa Clara University Undergraduate Programs help us with the cost of 
developing our frugal cervical cancer diagnostic. The funding we received was put towards 
designing an assay that validates the ability of successfully screening for certain biological markers 
specific to stage 0-1 cervical cancer. Due to the variety of biomarkers it was necessary to obtain 
multiple enzyme kits, antibodies, and reagents necessary to screen for the biomarkers and produce 
the desired colorimetric readout. From there, we worked on designing a method which screens for 
these markers in a way that is conducive to the environment in which it will be used. We requested 
a total of $2,800 and received $2,500. A detailed budget is located in Appendix A. 
 
2.5.3 Timeline 
Refer the Gantt Chart in Appendix B for a graphical representation of our time-line. 
 
Fall Quarter 
During the first few months of our project we identified the need for a low-cost cervical cancer 
diagnostic in developing countries. After identifying the problem (a high rate of incidence of 
cervical cancer in low-resource settings compared to the developed world), we worked hard to 
understand how this problem could best be addressed and what current methods were being used 
to address it.  Our first task was to truly understand the disease progression.  From there, we 
identified current screening and prevention methods including medical standards as well as 
methods that are currently being deployed in low-income countries.   
 
In recognizing that each country has its own unique factors that influence the way in which a 
problem propagates and can be addressed, we partnered with three public health students through 
the Engineering World Health program, who helped us discern which country would be the most 
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viable place to deploy our device in.  These students helped us to identify Tanzania as a viable 
option, and worked with us to network with healthcare professionals as well as organizations in 
the country.  With their help as well as the help of Frugal Innovation Hub, we partnered with the 
Buturi Project.  Through this connection as well as interviews with many other professionals and 
experts in the field, we were able to gain a deeper understanding of the needs in the country as 
well as validate that our device and it’s design would be useful and accepted in the country. 
Finally, we performed literature searches on the biomarkers present in HPV and cervical cancer.    
  
Winter Quarter 
At the beginning of the quarter we continued our biomarker search, narrowing down the panel of 
potential biomarkers utilizing a checklist that ensure it was present in detectable levels in the urine 
as well as specific to HPV or cervical cancer.  After identifying several markers, we wrote 
protocols and began to run experiments in the lab. Additionally, we narrowed down our biomarkers 
from three biomarkers to two and decided to run ELISA assays to detect the biomarkers over 
assays that we initially designed. 
 
Spring Quarter 
We ran and optimized ELISA assays for p16 and spermine and began the optimization process for 
incorporating the biomarkers into a lateral flow assay. We presented our diagnostic at the Global 
Health and Innovation Conference held at Yale University in April.  
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CHAPTER 3: Subsystem- Target Analytes 
3.1 Evolution of Biomarkers 
Our initial panel of biomarkers was composed of three different compounds, each of which served 
a specific purpose for the diagnostic. These were: the HPV protein capsid L1, which was 
upregulated during cases of HPV, but absent in CC; the Polyamine Spermine, which is a general 
cancer biomarker; and p16, a cyclin dependent kinase inhibitor that has been recommended by the 
World Health Organization as a biomarker of CC.[21] Therefore, by using the three biomarkers in 
parallel we would be able to distinguish between instances of HPV and CC. A positive CC 
diagnosis would consist of the presence of both Spermine and p16, but the absence of the L1 capsid 
(Table 4).  
 
Table 4: Initial Biomarkers and Expected Readout 
 No 
Disease 
Low Risk 
HPV Infection 
High Risk 
HPV Infection  
General 
Cancer 
Cervical 
Cancer 
Spermine - - - + + 
p16 - - +/- - + 
HPV Protein 
Capsid L1 
- + + - - 
 
3.2 Human Papillomavirus L1 Protein Capsid 
The HPV protein capsid L1 is the main protein associated with the virus, making up 90% of the 
total protein on the virus surface. This capsid is unique, because unlike other biomarkers it is 
abundant during infection, less present during the precursor lesions, but then nonexistent in 
carcinomas.[22] Therefore, we were going to use this biomarker to distinguish a simple HPV 
infection from the more serious lesions or cervical cancer. However, as we went through the 
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selection criteria cycle, we found several issues with the biomarker. The first issue is that although 
the viral load in urine is recorded, the exact concentration of the protein in urine has not been 
researched[23] [24] In addition, our preliminary estimation of the protein concentration indicates 
that it would not be detectable using the low cost and deployable methods that we had been 
considering.[23] [24] The only methods that were feasible for detection of the estimated 
concentration are not compatible with the infrastructure or resources of Tanzania.  
 
3.3 P16 
P16 is a cyclin-dependent kinase inhibitor that is upregulated in cervical cancer and precancerous 
cervical tissue.[25] In 2012, the College of American Pathologists (CAP) and the American 
Society for Colposcopy and Cervical Pathology (ASCCP) recommended the use of p16 for 
cervical cancer diagnosis. In 2014, the World Health Organization became the first global 
organization to issue a written recommendation for its use; therefore, we chose this biomarker to 
be our cervical cancer specific marker in our urinalysis device.[26]  
 
In healthy cells, p16 serves as a tumor suppressor protein, as it is essential in the regulation of the 
cell cycle. P16 regulates the Rb pathway by inactivating the cyclin-dependent kinase that 
phosphorylates Rb; thereby decelerating the cell cycle and preventing unregulated cell 
proliferation.[28] In high risk HPV and CC, p16 is over expressed and accumulates in cells is 
due to the misregulation of the Rb pathway. HPV infections that are transforming into CC have 
an increased expression of the viral oncoprotein E7, which disrupts pRB, a key regulator in the 
Rb pathway. This misregulation results in the overexpression of p16 via a negative feedback 
loop.[25]  
 
Although the concentrations of p16 in urine in individuals with cervical cancer are not yet 
published, Dr. Brenda Hernandez at the University of Hawaii is currently conducting research 
that verifies that p16 is secreted into the urine in the diseased state. We look forward to her paper 
once it is published that at we can develop our diagnostic with the concentration of p16 in mind. 
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3.4 Spermine 
Although HPV is the known precursor for cervical cancer, because of the variability of the 
infection and its numerous strains, it is necessary to test for another biomarker that may be 
indicative of a serious disease, and therefore confirm that the patient should definitely seek medical 
attention. The role of polyamines in cancer is still unconfirmed, but many studies have confirmed 
the upregulation of these compounds in the serum, plasma, and urine of cervical cancer patients. 
Current research suggests that their oxidation products have immunosuppressive effects, which 
would explain their relevance to cancerous tissues.[17] 
 
Three polyamines are frequently reported in literature: putrescine, spermidine, and spermine.  
Often these molecules are pooled to provide a larger concentration of polyamines to measure. 
When looking into each molecule individually and how their expression level changed due to 
various diseases, we settled on spermine as being our final biomarker.  Unlike the other two 
polyamines, which are upregulated by all diseases in the urinary system, spermine is 
downregulated by other diseases of the urinary tract while upregulated by cervical cancer.   
 
In the urine of a healthy subject, spermine is present at concentrations of 0.76 micromoles per 
gram, which converts to approximately 1979 nanograms per milliliter.[17] [28] When looking at 
spermine concentrations in subjects with cervical cancer, there was a calculated six fold increase 
in the concentration of spermine in the urine. The urine of a cervical cancer patient has 4.89 
micromoles per gram of spermine, meaning that they have 12,705 nanograms per milliliter, which 
is 12.7 micrograms per milliliter.[17] [28] These factors made spermine an ideal biomarker to 
validate that a person’s HPV had progressed into cervical cancer.   
 
3.5 Final Biomarker Selection 
Therefore, our final diagnostic panel consisted of two biomarkers, p16 and spermine (Table 5). If 
a woman were to use the diagnostic and have neither appear on the lateral flow assay, then one 
could conclude that she most likely has no disease or a low risk HPV infection. If only p16 were 
to appear, then it is possible that the woman has high grade lesions, as p16 is upregulated in the 
case of CIN2 and CIN3. Similarly, if only spermine were to show up on the assay, then one could 
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conclude that the woman either has a urinary cancer, or her body is expressing some sort of 
dysfunction that led to the upregulation of the biomarker. In both these cases we would recommend 
that she see a medical professional for a general examination. Finally, if both biomarkers were 
present on the diagnostic then the patient would be told that they are expressing signs of cervical 
cancer, and would be referred to a clinic or medical practitioner who could perform a more 
thorough examination for cervical cancer and potentially advise them on treatment options.  
 
Table 5: Final Biomarkers and Expected Readout 
 No Disease or Low 
Risk HPV Infection 
High Risk HPV 
Infection  
General 
Cancer 
Cervical Cancer 
Spermine 
- - + + 
p16 
- +/- - + 
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CHAPTER 4: Subsystem- Detection System 
4.1 Evolution of Design 
Initially, we planned on designing enzymatic assays for our biomarkers.  Different enzymatic assay 
techniques were researched and protocols were written for each of the biomarkers that were 
identified. The enzymatic assay designed for p16 utilized a cyclin-dependent kinase colorimetric 
assay. This cyclin-dependent kinase ATP-ADP Glo Assay obtained from Promega involves the 
conversion of ATP to ADP via the p16 kinase. When the p16 kinase is active, it is able to convert 
ATP to ADP, creating a bright green readout. When the kinase in inhibited by staurosporine, it 
cannot convert ATP to ADP resulting in no colorimetric readout. Since this assay was not 
colorimetric, we would not be able to incorporate it into our device, as one of our constraints is a 
colorimetric readout (Appendix C). 
 
The polyamines enzymatic assay involved the conversion of the polyamines spermine, 
spermidine, and putrescine into to hydrogen peroxide via polyamine oxidases. The hydrogen 
peroxide formed would then react with ABTS, a colorimetric reagent, to give a blue colored 
output that could be visible by the eye.   Though this method is widely used to quantify the 
amount of polyamines present in a sample, it is not specific to polyamines present in urine as 
there may be other natural sources of hydrogen peroxide due to biological metabolism functions.   
 
Although these were all functional assays, they cannot be easily be incorporated into a Lateral 
Flow Assay (LFA), which is our final product. LFAs utilize antibodies to detect the presence of 
analytes; therefore, we made the transition from enzymatic assays to enzyme-linked 
immunosorbent assays (ELISA). ELISAs are plate-based assays that are used to detect and 
quantify biomolecules, such as proteins, antibodies and hormones.[29] It is a quick and simple test 
that produces a colored product related to the amount of analyte in the sample [30]. They are 
typically carried out in 96-well polystyrene plates that are designed to bind to antibodies and 
proteins by immobilizing the reagents. Since the reagents are immobilized on the plate, it is 
possible to easily separate bound analytes and unbound molecules in a sample. This ability to wash 
off nonspecific molecules makes ELISAs great tools for detecting and quantifying analytes in a 
crude product, [30] such as urine. Since our LFA will use antibodies to detect the biomarkers, 
29 
 
ELISA assays can be used as a proof of concept to verify that we can differentiate between the 
healthy and diseased state, run the assay at relevant temperatures, and detect the analyte in urine.  
 
4.2 p16 ELISA Assay and Results 
The p16 sandwich assay was purchased from MyBioSource (Appendix D1). The assay comes 
with the p16 antibody conjugated to the bottom of the plate (Figure 2). The urine sample, or 
buffer, is added to the plate, and if p16 is present, it will bind to the antibody. The HRP 
conjugated antibody is added and will bind to the other side of p16, like a sandwich. Then the 
HRP substrate is added to the system and results in an enzymatic reaction that turns the solution 
blue. The blue color is directly proportional to the amount of p16 present in the sample. 
 
Figure 2: P16 Sandwich ELISA Assay. 
 
4.2.1 Differentiating Between the Healthy and Diseased States 
Since the levels of p16 in urine of individuals with cervical cancer are not yet published, the assay 
was unable to be run at concentrations of a healthy and diseased individual. However, we ran the 
assay at low concentrations to show that small amounts of p16 can be detected using this assay. 
Although the detection range was said to be 6.25 pg/mL - 200 pg/mL, we were able to comfortably 
detect as low as 5 pg/mL, as shown by the visible color in the wells (Figure 3). There was some 
detectable color at 2.5 pg/mL, but more optimization would be required to comfortably detect that 
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concentration (Figure 3A). Since p16 should not be in the urine of healthy individual,we were 
able to show that the assay is extremely sensitive and can be a valid option for differentiating 
between the two states.  
 
Figure 3: Qualitative Data from Varying Concentrations of p16. (A) Image of assay when 
run below recommended detection range. Able to reliably see color at 25 pg/mL. (B) Image of 
assay when run at lower end of detectable range. 
 
4.2.2 Temperature Optimization 
Assay was conducted the recommended temperature of 37℃ and at room temperature. The assay 
was run at room temperature verify that it could be run in substandard conditions, as incubators 
are not common in our target population. Temperatures in Tanzania range from 18-31℃ [31] and 
the room temperature of the lab was around 20℃. Since the assay was still functional, as indicated 
by the appearance of a blue color at both temperatures, we can conclude the assay will work in 
Tanzania (Figure 4). 
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Figure 4: Qualitative p16 Data for Temperature Optimization. Image of assay run at both 
recommended incubation temperature as well as room temperature.   
 
4.2.4 Fluid Optimization 
Due to the non-invasive design, and subsequent urinalysis testing of the biomarkers, we had to 
confirm that the results of the ELISA were comparably consistent for detecting the analyte in urine, 
as they were in the buffer that was provided. Therefore, to determine if the assay would be 
functional in detecting p16 in urine, we replaced the buffer with urine at the strongest concentration 
of urine possible. This was done intentionally, to test the most suboptimal conditions possible. P16 
was then added to the urine at varying concentrations, and placed in the wells where the ELISA 
reaction took place (Figure 5). Qualitatively, we were able to detect p16 in urine and in buffer, as 
seen by the presence of the blue color at all four concentrations. Additionally, the gradient of color 
progressed from light to dark in both assays, confirming that urine did not impede the reaction 
between the analyte and the antibodies. Therefore, the p16 ELISA assay is a functional assay for 
the detection of p16 in urine.  
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Figure 5: Qualitative p16 Data for Fluid Optimization. Images of assays run in buffer 
supplied with ELISA kit and of assay run with artificial urine show no distinct difference.   
 
4.3 Spermine ELISA Assay and Results 
A Spermine competitive ELISA was used to detect for polyamines in the urine. The ELISA 
assay obtained from MyBiosource (Catalog#MBS731360), was tested at basal concentrations as 
well as diseased concentrations to ensure that there is no colorimetric signal obtained in the basal 
conditions and only in the diseased condition (Appendix D2). The ELISA works by a 
competitive ELISA mechanism which involves a well-plate already pre-coated with an anti-
spermine antibody.  That antibody binds spermine molecules that are present in the urine sample.  
After the sample is applied to the wells, an HRP conjugated antibody reagent is added.  This 
reagent is highly specific to the pre-coated antibodies that do not have any spermine bound to 
them.  Because of this, when there is no spermine in the solution, or lower levels, which can be 
correlated to the levels present in a healthy human, a darker blue color is produced because more 
colored reagents are able to bind.  Conversely, when there are higher levels of spermine in the 
urine, as a diseased individual would, less of the HRP color reagent can bind, producing a lighter 
blue color.   
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Figure 6: Spermine Competitive ELISA Assay 
4.3.1 Differentiating Between the Healthy and Diseased States 
Running the spermine ELISA at different concentrations of spermine enabled for the successful 
differentiation between the healthy and diseased states. A healthy individual has about 0.2 ng/mL 
of spermine in their urine and an individual with cervical cancer has 2 ng/mL. [17] Since the 
spermine ELISA is a competitive assay, the well with the healthy amount of spermine is a deeper 
blue, because there is less spermine to compete with the antibody and the well with the diseased 
amount of spermine is clearer in color, since there is more spermine to compete (Figure 6). After 
running the assay and taking pictures, a plate reader was used to measure the absorbance of each 
well. The data was normalized against a no spermine condition, and the data was graphed 
(Figure 8). Therefore, the data qualitatively and quantitatively differentiates between the two 
states. 
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Figure 7: Qualitative Spermine Data Differentiating Between Healthy and Diseased States. 
Image of assay when run with concentrations of spermine that exist at both the healthy and the 
diseased states.   
 
 
Figure 8: Quantitative Spermine Data Differentiating the Healthy and Diseased States. 
Healthy condition represented with triangles and diseased condition represented with squares.  
 
4.3.2 Temperature Optimization 
As done with the p16 ELISA assay, the spermine ELISA assay was also optimized for temperature.  
The ELISA assay required a 37 ℃ incubation.  The assay was run at room temperature verify that 
it could be run without the use of any extraneous equipment that is not accessible in low-income 
settings such as in Tanzania. The tests indicated that the assay was still functional given that there 
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was a clearly more intense blue readout for the healthy individual compared to the lighter blue 
produced for the diseased individual at both temperatures.   (Figure 9). 
 
 
Figure 9: Qualitative Spermine Data for Temperature Optimization. Images of assay run at 
both the recommended temperature from distributor as well as at room temperature 
 
Figure 10: Quantitative Spermine Data for Temperature Optimization.  37 ℃ condition 
represented with triangles and room temperature condition represented with squares.   
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4.3.4 Fluid Optimization 
As performed with the p16 ELISA assay above, the fluid used in the Spermine assay needed to be 
optimized to suit the non-invasive and urinalysis design of the biomarkers assays. We had to 
confirm that the results of the ELISA were comparably consistent for detecting the analyte in urine, 
as they were in the buffer that was provided. Therefore, to determine if the assay would be 
functional in detecting spermine in urine, we replaced the buffer with urine. Spermine was added 
to the urine at varying concentrations, and placed in the wells where the ELISA reaction took place 
(Figure 11). Due to the competitive nature of the Spermine ELISA, presence of analyte was 
confirmed by an absence of color. Therefore, progression of color from dark to light confirmed 
that urine did not impede the reaction between the Spermine and the Spermine antibodies. 
Therefore, the Spermine ELISA assay is a functional assay for the detection of Spermine in urine.  
 
Figure 11: Qualitative Spermine Data for Fluid Optimization. Images of assays run in buffer 
supplied with ELISA kit and of assay run with artificial urine show no distinct difference.   
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Figure 12: Quantitative Spermine Data for Fluid Optimization. Buffer condition represented 
with triangles and urine condition represented with squares.  
 
4.4 Final Design Description 
After testing the reagents that were necessary to screen for our biomarkers, we began researching 
how to incorporate these reagents into a lateral flow assay (LFA).  A LFA uses similar reagents to 
ELISAs but the reagents are exposed to the fluid being analyzed through a different method.  
ELISAs are performed in a liquid solution with antibodies for the analyte being tested pre-coated 
to the bottom of the plate.  These antibodies then bind to the analytes in the fluid being tested.  
Once the fluid being analyzed can interact with the pre-coated antibodies, a colored reagent 
specific to the analytes is added and subsequently binds to produce a colorimetric output that can 
be interpreted quantitatively and qualitatively.   
 
LFAs require all the same biological reagents as an ELISA but instead utilize a solid technique 
that capitalizes on the flow of the fluid being analyzed through the assay itself.  The fluid being 
analyzed reacts first with the colored reagents specific to the analytes being screened for.  Then, 
as the fluid flows through the assay, they react with the antibodies that are specific to the analytes 
being screened for.  These antibodies are printed in a single line and when they catch onto the 
analyte a visible color is produced due to the aggregation of the colored reagent attached to the 
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analyte.  This method is solely qualitative.  We are hoping to incorporate the antibodies from the 
ELISA into our LFA given that we have verified are capable of testing for our analytes.   
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CHAPTER 5: System Integration 
5.1 Lateral Flow Assay Components 
LFAs are beneficial for our purposes because these tests typically have long shelf lives and do 
not require refrigeration or special care, like many other diagnostic tests. Another benefit of an 
LFA is that it requires minimal training and no additional processing after use, which makes it 
well suited to act as a field based diagnostic necessary for our target population, Tanzania. 
Because these tests are powered only by capillary action, they do not require an energy source 
and provide a reading within 20 minutes of testing. Similarly, they only require a small amount 
of liquid sample to produce a result. In terms of sensitivity, LFA’s have better sensitivity and 
specificity than other well-established methods under optimal conditions; however, depending on 
the analyte and antibody used there may be cases of low biomolecule affinity. [32] 
 
A lateral flow assay works through multiple membranes with varying functions, which come 
together to allow for a qualitative colored readout that is easily understand by the user.  The 
membranes and components in an LFA are pictured in (Figure 13A).  The first membrane is the 
sample application pad.  The sample application pad is where the fluid to be analyzed is applied. 
In this case, our fluid would be urine, which the sample application pad is meant to filter as it 
moves through due to capillary action. The fluid then flows into the conjugate pad, which 
contains the colored reagents necessary to produce a colorimetric output.  Often, colored 
nanoparticles are conjugated to antibodies specific to the biomolecules being screen for.  These 
nanoparticles are then seeded onto the conjugate pad so that when the fluid runs through this pad, 
the antibodies will bind specifically to the molecules and move with them throughout the rest of 
the membrane.  Another low-cost option that is sometimes used is Horseradish Peroxidase (HRP) 
which is the colored reagent we utilized in our ELISA assays.  After the bind to the colored 
reagents, they then flow into the analytical membrane which contains test and control lines.  Test 
lines contain antibodies that are specific to the biomolecules.  When the analyte is present, it will 
bind to the control line, allowing for the colored nanoparticles to aggregate and produce a 
colored line that can be seen with naked eye.  The control line contains antibodies that are 
specific to the conjugated nanoparticles.  This final line is necessary to prove that even with no 
analyte present, the device is still functional as any fluid can move the particles seeded in the 
conjugate pad throughout the entire membrane to the test line.  Our CERVIS LFA would have a 
40 
 
line specific to p16, a test line specific to spermine, and a control line specific to the antibodies 
conjugated to the colored particle of our choice (Figure 13B).   
A)   
B)  
Figure 13: Components of a Lateral Flow Assay. (A) Diagram of the different membranes and 
pads necessary to incorporate into a Lateral Flow Assay. (B) Diagram of LFA specific to 
CERVIS with urine being analyzed for the analytes p16 and spermine. 
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5.2 Optimization Process 
There are various steps that must be taken to design a functional lateral flow assay.  When 
designing a lateral flow assay, it is suggested to first design half stick assays before incorporating 
all pads and membranes necessary for a full LFA.   
 
The half stick assay consists of the analytical membrane as well as the test and control lines.  The 
analytical membrane is normally a nitrocellulose membrane.  The properties of the nitrocellulose 
membrane used vary, so it is important to choose a membrane that works best for your test 
depending on the fluid you are analyzing, the analytes that are being screened for, as well as the 
functionality of the test.  Membranes that are more porous will allow for the fluid to flow faster, 
producing a result faster.  However, the speed may compromise the amount of time that the test 
lines can interact with the analytes present in solution, which could in turn impact how clear and 
intense the colorimetric result appears.  Optimizing the half stick assay will not only require 
considering what membrane will be used but also which antibodies and colored reagents.  We have 
already identified antibodies capable of screening for our analytes using ELISAs, however, 
throughout the LFA design process it may be useful to utilize antibodies from other manufacturers 
to observe which antibody produces the best result.   
 
Once the half stick assay is optimized, the other components of the LFA can be incorporated and 
the entire assay can be further optimized.  The sample pad will need to be optimized to filter out 
unwanted analytes.  Materials often used are glass fiber, cellulose, cotton, and synthetic materials.  
The conjugate pad will be optimized by determining the volume of conjugate that can be absorbed 
onto the pad as well as released when fluid runs through it to ensure that there is no extra noise 
running through the analytical membrane that may produce unclear results.   
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CHAPTER 6: Costing Analysis 
6.1 Cost of Materials for Development 
As a device in the early stages of development, we still do not have an exact picture of the specific 
antibodies or materials that will be needed for the final device. However, a rough estimate can be 
made using the average costs of creating a lateral flow assay, and an estimation of the 
manufacturing price for our antibodies and antibody conjugated nanoparticles. Due to the existing 
mass production of lateral flow assays for a variety of purposes including pregnancy tests, glucose 
tests, biological threat agents, and HIV antibodies, there are companies that are already equipped 
to create and optimize each component of the lateral flow assay to the specifications of the analyte 
and antibody. As previously mentioned, the standard components of an LFA include the sample 
pad, the conjugate pad, the reaction matrix, the absorbent pad, and a membrane backing card. 
However, to manufacture an LFA for production and use also means the need for an upper casing, 
a membrane panel, a lower casing, a sample port, and protective housing for the device. 
Additionally, one will also need antibodies specific to the analyte, nanoparticle conjugated 
antibodies, and various reagents such as buffers, blocking agents, salts, etc. A report by The Royal 
Society of Chemistry estimates that in mass production, the sum of these components would 
average out to $0.22 per device. Almost 60% of this cost would be due to the cost of antibodies, 
19% is attributed to the packaging that is needed for the pouch, 9% for the membrane backing 
cards, and the rest to the reagents, yarn costs, plastic housing, and manufacturing equipment and 
power. We expect our device to cost slightly more than this due to the use of multiple antibodies 
in parallel, however, our highest estimates keep the device under $1 per product, and most likely 
around the $0.50 mark. [32] 
 
6.2 Expected Cost of Deployment 
Similarly, to the cost of the materials, the cost of deployment of our diagnostic is still unclear to 
us as we proceed through the early stages of device creation and development. This will depend 
significantly on the final size of each diagnostic, the partnerships that we make with hospitals in 
Tanzania, and the strength of the connections that we form with nonprofits based in Tanzania who 
serve the more remote villages. An important factor to note is that although it may be relatively 
cheap to get the diagnostics from the United States to Tanzania, our partners at The Buturi Project, 
who personally service the Buturi region, a large region of Tanzania containing several villages, 
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have stated themselves that travel to and between each village is extremely difficult. There are few 
functional roads and vehicles for transportation, and the ones that do exist are neither cheap or 
reliable. Although it proved difficult to find existing examples of cost for lateral flow assays in 
Tanzania, we were able to locate a summary of transportation costs for the area. As according to a 
paper published by researchers of the Indian School of Business and University of California, 
Santa Cruz, the average village in Tanzania has 2,843 residents and is located 5.7 km from the 
nearest market center. This trip would cost approximately $1.60. However, an average village is 
located almost 65 km away from a major town, which increases the cost of the trip to $4.70. [33] 
Even though we consider that the cost would be divided among 20-100 devices, it would still add 
a significant amount to the cost of the device. Therefore, we would hope to manufacture the device 
within the country of Tanzania, and therefore eliminate any international transportation costs, and 
hopefully some of in the local costs as well.   
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CHAPTER 7: Engineering Standards and Ethics 
The engineering standards that affect our design most are economic, manufacturability, social, and 
health and safety. Since we are planning our deploying our device in Tanzania, we had to take 
their economy into account. We sought to develop low cost device, so that people of all 
socioeconomic backgrounds would have the opportunity to get tested for cervical cancer.  
 
Very early on in the process, we considered the manufacturability of our product. We want the 
product to be manufactured in the country of deployment, so that the clinics do not run out of the 
diagnostic while waiting for it to go through border control. Additionally, this would help the 
economy, as it would give the job of manufacturing the device to those who live in Tanzania.  
 
The social considerations are a large factor in our project. Women’s health is not well understood 
or discussed in Tanzania. Additionally, there is a stigma surrounding sexually transmitted diseases. 
This consideration inspired us to design an educational component that will be implemented with 
our product to educate those in the community about the risks of unprotected sex, the development 
from HPV to cervical cancer, and the necessity of getting tested regularly. Another social 
constraint we faced as invasiveness. We briefly considered making a device, similar to a tampon, 
that tested cervicovaginal fluid, but were concerned that it would not be socially acceptable.  
 
The most important factor that we considered was health and safety. Our goal is to improve the 
health of women by enabling them to test for cervical cancer in its early stages. We want to help 
women around the world and facilitate the education of the relationship between cervical cancer, 
HPV, and sexually transmitted diseases. Since our product is a diagnostic, we are focused on 
making sure our test is sensitive and accurate, so it does not give false negatives and limited false 
positives.  
 
Since our device is a cervical cancer diagnostic, the ethical concerns surrounding our device 
revolves around manufacturability and reliability. We must use Good Manufacturing Practices to 
develop and manufacture the product that will eventually be used to diagnose women with cervical 
cancer in various locations. Even though we are not treating women for cervical cancer, we must 
be certain that we have low rates of false positives and false negatives. False positives would result 
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if CERVIS says a woman has cervical cancer, when further tests confirm that she does not. False 
negatives occur when CERVIS says a woman does not have cervical cancer, when they do. 
Therefore, we must develop the device to limit the potential of false positives and false negatives 
and conduct iterative testing to prove accurate diagnoses. False negatives have a greater potential 
for harm than false positives, but it is important to limit both.  
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CHAPTER 8: Future Work 
8.1 Global Health and Innovation Conference 
In addition to conducting research and working in the lab to validate our assays and designing our 
LFA, we had the opportunity to pitch our product to a panel of experts, ask questions, and receive 
feedback at Unite for Sight’s Global Health & Innovation Conference (GHIC). GHIC is the world's 
leading and largest global health conference as well as the largest social entrepreneurship 
conference that is held annually at Yale University. [34] We asked for advice on selecting 
biomarkers to differentiate HPV infection, CIN-1, and advanced cancer and for connections to 
advisors in our target population who can lend guidance on feasibility, field testing, and eventual 
adoption of our device. Although we were not able to receive advice on selecting additional 
biomarkers, we received feedback on expanding our target population to women who are victims 
of sexual abuse who may prefer a noninvasive option. Additionally, we were able to connect with 
CapraCare, a nonprofit organization in Haiti that educates people on cervical cancer, tests for the 
disease using visual inception by acetic acid (VIA), and treats it using cryotherapy. They are 
already gathering the data and have the infrastructure and connections we would need to deploy 
our device. We also made connections that will possibly result in additional funding. The 
conference contributed to our learning by expanded the scope of our project and reinforced the 
importance of this device. The product could save the lives of and positively impact a larger group 
of women than we previously thought possible. 
 
8.2 Next Steps 
Now that we have the reagents necessary to screen for our biomarkers, we are hoping to design an 
easy to use diagnostic known as a lateral flow assay (LFA).  Currently, we have some of the 
reagents and materials necessary to design a lateral flow assay.  We have multiple nitrocellulose 
membranes from Sartorius Membranes to optimize the analytical membrane.  However, we must 
obtain antibodies specific to the analytes to create the test and control lines that will capture 
analytes flowing through the assay.  Additionally, we must still purchase antibodies conjugated to 
colored nanoparticles that will produce the colored readout on the test and control lines.  Once 
these reagents are obtained, half-stick assays can be developed to validate that the analytes can 
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still be measured using this new method.  Finally, once the half-stick assays are validated, sample 
pads, conjugate pads, and absorbent pads must be obtained to develop the full lateral flow assay.   
 
Additionally, we are in active communication with the professionals we met at the Global Health 
and Innovation Conference, through which we have the potential to establish a deployment 
strategy.  We are hopeful that our device in combination with these connections will result in the 
prevention of unnecessary loss of life due to cervical cancer 
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Appendices 
Appendix A: Budget 
Project Area Material Cost 
Protein Detection Protein detection kit (chemicals for 
detection of biomarkers) 
$1000 
 Filter paper  $50 
 Standard bioengineering consumables 
(eppendorf tubes, pipette pins, well 
plates) 
$50 
 Simulated urine $20 
Existing products Reagent Strips for Urinalysis 100ct $50 
Cost of actual 
protein 
Mock P16 Inhibitor $158 
 CDKN2A Assay Kit $548 
 HRP $76 
 p16 ELISA  $435 
 Spermine ELISA $455 
Amounts 
Requested 
Requested from undergraduate grants $1,800 
 Requested from Xilinx grant $1000 
ii 
 
 Total Requested $2,800 
Amounts Received Grants awarded by School of 
Engineering 
$1,500 
 Grants awarded by Engineering World 
Health  
$1,000 
 Total Awarded $2,500 
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Appendix B: Gannt Chart 
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Appendix C: Proposed p16 ADP GLO Protocol 
 
Kinase Reaction for Cdk2/Cyclin A2 kinase enzyme system  
Normally in a 96 well plate they use 25 μL as the total reaction volume 
Make a 100 μL kinase reaction and then split into 4 well plates for a 25 μL: 25 μL: 50 μL 
final reaction to record luminescence  
 
● Initial prep 
○ Dilute 0.5 μL of 0.1M DTT in 200 μL of 5x reaction buffer to form Reaction 
Buffer A 
● Kinase reaction 
○ Control reaction: 100 μL to be split into 4 trials  
■ Add 75.5 μL of DI water to 20 μL Reaction Buffer A  
■ Add 4 μL Histone H1 to reaction 
■ Add 0.5 μL of ultra pure ATP 
■ 0 μL of Kinase 
○ 0.63 Kinase Reaction: 100 μL to be split into 4 trials  
■ Add 74.9 μL of DI water to 20 μL Reaction Buffer A  
■ Add 4 μL Histone H1 to reaction 
■ Add 0.5 μL of ultra-pure ATP 
■ Add 0.63 μL of Kinase 
○ 1.26 Kinase Reaction: 100 μL to be split into 4 trials  
■ Add 74.2 μL of DI water to 20 μL Reaction Buffer A  
■ Add 4 μL Histone H1 to reaction 
■ Add 0.5 μL of ultra-pure ATP 
■ Add 1.26 μL of Kinase 
○ 3 Kinase Reaction: 100 μL to be split into 4 trials  
■ Add 72.5 μL of DI water to 20 μL of Reaction Buffer A  
■ Add 4 μL Histone H1 to reaction 
■ Add 0.5 μL of ultra-pure ATP 
■ Add 3 μL of Kinase 
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○ Incubate for 10 minutes  
● ADP depletion 
○ Add 100 μL of ADP Glo Reagent (1:1:2 of Kinase Rxn:ADP Glo: Kinase 
Detection Reagent) 
○ Incubate for 40 minutes  
● ADP detection 
○ Add 50 μL of reaction to 4 wells 
○ Add 50 μL of Kinase Detection Reagent to each of the 4 wells 
○ Incubate for 30 minutes 
● Spectrophotometer readings 
○ Take absorbance readings of well plate 
○ Added Kinase Detection Reagent into two separate wells (50 μL) to act as a blank 
○ Take absorbance readings again 
○ Take luminescence readings 
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Appendix D: ELISA Protocols 
Appendix D1: P16 ELISA 
Sensitivity of this assay is 6.25 pg/mL - 200 pg/mL. 
1.  Bring all reagents and samples to room temperature (18 °C-25 °C) naturally for 30 min 
before starting assay procedures. The MicroELISA Strip plate is detachable, detach 
unused strips from the plate frame, return them to the foil pouch with the desiccant pack, 
and reseal for preventing damps. 
2. Standard wells, Sample wells and Blank/Control wells 
a. Add Standard 50 μL to each Standard well 
b. Add Sample 50 μL to each sample well 
c. Add Sample Diluent 50 μL to each Blank/Control well.  
3. Add 100 μL of HRP-conjugate reagent to each well, cover with a Closure Plate 
Membrane and incubate for 60 minutes at 37 °C or room temperature. 
4. Wash the plate 4 times in wash buffer (dilute 20x to 1x using deionized water):  
a. Manual Washing – Dump the incubation mixtures of the wells into a sink or 
proper waste container. Using pipette or squirt bottle, fill each well completely 
with Wash Solution (1x), after about one minute’s standing, invert and hit the 
plate onto absorbent papers or paper towels until no moisture appears. Repeat this 
procedure four times.  
5. Add Chromogen Solution A 50 μL and Chromogen Solution B 50 μL to each well 
successively and protect from light to incubate for 15 minutes at 37 °C or room 
temperature. 
6. Read the optical density at 450 nm using plate reader. 
  
Appendix D2: Spermine ELISA 
Sensitivity of this assay is 0.5 - 10 ng/mL 
1. Bring all reagents and samples to room temperature (18 °C-25 °C) naturally for 30 min 
before starting assay procedures. 
2. Standard wells, Sample wells and Blank/Control wells 
a. add Standard 100 μL to each Standard well 
b. add Sample 100 μL to each sample well and 10 μL of balance solution 
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c. add 100 μL of PBS into the blank control well  
3. Add 50 μL of conjugate to each well and mix thoroughly. Cover and incubate the plate 
for 1 hour at 37 °C or at room temperature.  
4. Wash the plate 4 times in wash buffer (dilute 20x to 1x using deionized water):  
a. Manual Washing – Dump the incubation mixtures of the wells into a sink or 
proper waste container. Using pipette or squirt bottle, fill each well completely 
with Wash Solution (1x), after about one minute’s standing, invert and hit the 
plate onto absorbent papers or paper towels until no moisture appears. Repeat this 
procedure four times.  
5. Add Substrate A 50 μL and Substrate B 50 μL to each well successively and protect from 
light to incubate for 15 minutes at 37 °C or at room temperature. 
6. Read the optical density at 450 nm using a plate reader. 
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Appendix E: Assessment of Current Diagnostic Options 
The rating system is from 0, being the lowest, to 5, being the highest. We believe the factors each 
diagnostic is ranked against are important in a successful and high-impact product. The rankings 
were determined after extensive review of the methods of these technologies and outcomes. If the 
current diagnostic completely misses one of our requirements, they received a score of 0 or 1 in 
that factor. Additionally, the ranking generally compares one diagnostic method against the others 
and considers ease of use.  
 
Table 1: Evaluation of Current Technologies Utilized for Diagnosing Cervical Cancer 
 Visual 
Inspection by 
Acetic Acid / 
Iodine 
Pap Test Colposcopy Roche CINtec 
Histology Test  
Minimal 
Invasiveness  
3 
Requires only 
one visit. 
 
1 
Metal / plastic 
speculum used 
to open walls of 
vagina to get to 
cervix. Sampler 
collects cells to 
be tested. 
Multiple visits 
necessary. 
1 
Closer 
examination of 
cervix. 
Colposcope 
used. 
Only done when 
abnormal pap 
test result 
obtained.  
2 
Tissue biopsy 
necessary. The 
assay is only run 
if there are 
abnormalities.  
High 
Success Rate 
2 
Resources used 
on unnecessary 
treatment of 
women who are 
free of 
2 
Only frequent 
cervical 
screening can 
detect HPV 
infections.  
3 
More specific 
analysis of 
histology and 
cytology 
following a pap 
5 
FDA approved 
with the 
ATHENA trial 
that surveyed 
more than 
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precancerous 
lesions in a 
single-visit 
approach.  
test. 47,000 women  
*Specific to 
HPV 
 
Easy 
Accessibility 
5 
Minimal 
infrastructure 
needed: exam 
area and table, 
trained health 
professionals, 
speculum, and 
acetic acid. 
2 
Not easily 
accessible in 
low-income 
countries.  
Follow up tests 
necessary with 
doctors  
1 yr. and 3-5 
yrs. 
2 
Not easily 
accessible in 
low-income 
countries.  
2 
Not easily 
accessible in 
low-income 
countries.  
Low Cost 5 
Low start-up 
and sustaining 
costs. 
 
3 
$50 to $200 per 
test. 
1 
$100-800 per 
test (already 
following pap 
test). 
- 
Not enough 
information on 
cost to be 
assessed. 
 
High 
Accuracy  
2 
Naked eye used 
to identify color 
changes on 
cervix after 
application of 
chemical  
3 
Looks solely at 
histology of the 
cells. 
Follow up tests 
are necessary.  
Needs to be in 
conjunction 
with an HPV 
3 
Looks solely at 
histology of the 
cells. 
4  
Numerous 
biomarkers 
used, including 
p16, which is 
recommended 
by the World 
Health 
Organization.  
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test. 
Expertise 
Necessary  
3  
Trained health 
professionals 
required to 
perform the 
procedure. 
1 
Specialized 
physician 
required to carry 
out procedures.  
1 
Specialized 
physician 
required to carry 
out procedures.  
2 
Specialized 
physician 
required to 
interpret results. 
Focus on 
Cervical 
Cancer over 
HPV 
2 
Not specific to 
cervical cancer 
and detects for 
HPV.  
2 
Need to run Pap 
test in 
conjunction 
with HPV test 
for best results.  
3 
This 
examination 
done after 
having 
abnormal pap 
smear. Positive 
results in the 
need for a  
Cervical biopsy.  
2 
Used to confirm 
the presence or 
absence of high-
grade cervical 
lesions utilizing 
HPV specific 
markers. 
 
 
 
 
  
